Determination of risedronate in human urine by column-switching ion-pair high-performance liquid chromatography with ultraviolet detection

An HPLC assay for the determination of risedronate in human urine was developed and validated. Risedronate and the internal standard were isolated from 5-ml urine samples in a two-part procedure. First, the analytes were precipitated from urine along with endogenous phosphates as calcium salts by the addition of CaCl2 at alkaline pH. The precipitate was then dissolved in 0.05 M ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid and subjected to ion-pair solid-phase extraction using a Waters HLB cartridge (1 ml, 30 mg) with 1-octyltriethylammonium phosphate as the ion-pair reagent. Following extraction, the analytes were initially separated from the majority of co-extracted endogenous components on a Waters X-Terra RP18 (4.6×50 mm, 3.5 μm) column. The effluent from the X-Terra was “heart-cut” onto a Phenomenex Synergi Polar RP (4.6×150 mm, 4 μm) column for final separation. UV detection (λ=262 nm) was used to quantitate risedronate in the concentration range of 7.5–250 ng/ml. Mean recovery was 83.3% for risedronate and 86.5% for the internal standard. The intra-day precision of the assay, as assessed by replicate (n=5) standard curves, was better than 6% RSD for all points on the standard curve. Within-day accuracy for the standards ranged from 96.3 to 106.1% of nominal. Inter-day precision for quality controls assayed over a 3-week period was better than 5%, while inter-day accuracy was within 90% of nominal. The assay was employed to analyze samples collected during a clinical pharmacokinetics study.